Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
CHUGAI PHARMACEUTICAL CO., LTD- founded in 1925- is committed to providing high-quality healthcare and improving people’s health, well-being and quality of life. With global horizon, Chugai is increasingly focusing on Research and Development (R＆D). Our mission today and tomorrow is to create exceptional added value in healthcare, and proceed to be a leading international health care company.
To service Taiwan, Chugai set up a Taipei branch company in 1988, and merged with HUEY MAW TRADING CO., LTD. to become CHUNG HUEY PHARMACEUTICAL CO., LTD. in 1991. In October 2001, the company officially changed the name to CHUGAI PHARMA TAIWAN and reran the business for marketing hospital-based products. Most of the pharmaceutical products import from Japan headquarters directly and part of them are toll manufacture locally; furthermore, CHUGAI PHARMA TAIWAN CO., LTD and SHUN HWA CO., LTD are responsible for marketing business to remain constant: to improving patient care.
Major products
GRANOCYTE (Recombinant Human Granocyte Colony-Stimulating Factor Preparation)
SIGMART (Anti Angina Pectoris Agent)
Company Name: Chugai Pharma Taiwan Ltd.
Address: 3Fl., No. 73, ZhouZi Street, Neihu District,Taipei 10493, Taiwan
Telephone: (02)2658-8800
Fax: (02)2658-8852
E-Mail: cpt@chugai.com.tw
Website: www.chugai-pharm.co.jp
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Taiwan’s current health minister reflects on Taiwan’s prestigious healthcare system, the problems in the first generation health insurance system that were fixed in the second, and strategies to rectify the…
Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future…
The Deputy Executive Secretary of Taiwan’s National Development Fund discusses the recent shift in focus from semiconductors to biotech investments; why this has been a huge success thus far and…
The Vice President of Merits Health Products discusses the company’s main opportunities and challenges of the past 25 years, which countries are among its top buyers and its future plans…
Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did a US-based company look to establish itself in Taiwan, and…
Over the past decade since its founding, what are some of the highlights in the transformation of Taiwan Advance Bio-Pharmaceutical Inc. (TABP) into a well established company? TABP was founded…
YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill…
Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp.…
Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API…
PAREXEL has been in Asia Pacific (APAC) since the company entered Japan in 1995. It chose Taiwan as its regional base of operations with the 2007 acquisition of APEX, a…
The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in…
See our Cookie Privacy Policy Here
